For NSCLC, clinical practice guidelines recommendations include testing the genomic biomarkers Epidermal growth factor receptor (EGFR), Anaplastic lymphoma kinase (ALK), Kirsten rat sarcoma (KRAS), B-RAF proto-oncogene (BRAF), and immunotherapy marker programmed death-ligand 1 receptor (PDL1). This evidence concerns the gene ALK and non-small cell lung carcinoma.